[1]Onyoh EF, Hsu WF, Chang LC, et al. The rise of colorectal cancer in asia: epidemiology, screening, and management[J]. Curr Gastroenterol Rep, 2019, 21(8): 36.
[2]Sieminska I, Baran J. Myeloidderived suppressor cells in colorectal cancer[J]. Front Immunol, 2020, 11: 1526.
[3]Meira LB, Bugni JM, Green SL, et al. DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice[J]. J Clin Invest, 2008, 118(7): 2516-2525.
[4]Anitei MG, Zeitoun G, Mlecnik B, et al. Prognostic and predictive values of the immunoscore in patients with rectal cancer[J]. Clin Cancer Res, 2014, 20(7): 1891-1899.
[5]Bronte V, Brandau S, Chen SH, et al. Recommendations for myeloidderived suppressor cell nomenclature and characterization standards[J]. Nat Commun, 2016, 7: 12150.
[6]Wang Y, Yin K, Tian J, et al. Granulocytic myeloidderived suppressor cells promote the stemness of colorectal cancer cells through exosomal S100A9[J]. Adv Sci (Weinh), 2019, 6(18): 1901278.
[7]Xu P, He H, Gu Y, et al. Surgical trauma contributes to progression of colon cancer by downregulating CXCL4 and recruiting MDSCs[J]. Exp Cell Res, 2018, 370(2): 692-698.
[8]De Cicco P, Ercolano G, Ianaro A. Thenew era of cancer immunotherapy: targeting myeloidderived suppressor cells to overcome immune evasion[J]. Front Immunol, 2020, 11: 1680.
[9]DiazMontero CM, Salem ML, Nishimura MI, et al. Increased circulating myeloidderived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicincyclophosphamide chemotherapy[J]. Cancer Immunol Immunother, 2009, 58(1): 49-59.
[10]Ouyang LY, Wu XJ, Ye SB, et al. Tumorinduced myeloidderived suppressor cells promote tumor progression through oxidative metabolism in human colorectal cancer[J]. J Transl Med, 2015, 13: 47.
[11]Siemińska I, Poljańska E, Baran J. Granulocytes and cells of granulocyte originthe relevant players in colorectal cancer[J]. Int J Mol Sci, 2021, 22(7): 3801.
[12]Dufait I, Schwarze JK, Liechtenstein T, et al. Ex vivo generation of myeloidderived suppressor cells that model the tumor immunosuppressive environment in colorectal cancer[J]. Oncotarget, 2015, 6(14): 12369-12382.
[13]Steggerda SM, Bennett MK, Chen J, et al. Inhibition of arginase by CB1158 blocks myeloid cellmediated immune suppression in the tumor microenvironment[J]. J Immunother Cancer, 2017, 5(1): 101.
[14]Nagaraj S, Gupta K, Pisarev V, et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer[J]. Nat Med, 2007, 13(7): 828-835.
[15]Deng J, Li J, Sarde A, et al. Hypoxiainduced VISTA promotes the suppressive function of myeloidderived suppressor cells in the tumor microenvironment[J]. Cancer Immunol Res, 2019, 7(7): 1079-1090.
[16]Kumar V, Cheng P, Condamine T, et al. CD45 phosphatase inhibits STAT3 transcription factor activity in myeloid cells and promotes tumorassociated macrophage differentiation[J]. Immunity, 2016, 44(2): 303-315.
[17]Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis[J]. Trends Cell Biol, 2019, 29(3): 212-226.
[18]Yang L, Huang J, Ren X, et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr1+CD11b+ myeloid cells that promote metastasis[J]. Cancer Cell, 2008, 13(1): 23-35.
[19]Ye TH, Yang FF, Zhu YX, et al. Inhibition of Stat3 signaling pathway by nifuroxazide improves antitumor immunity and impairs colorectal carcinoma metastasis[J]. Cell Death Dis, 2017, 8(1): e2534.
[20]Vetsika EK, Koukos A, Kotsakis A. Myeloidderived suppressor cells: major figures that shape the immunosuppressive and angiogenic network in cancer[J]. Cells, 2019, 8(12): 1647.
[21]Hiratsuka S, Goel S, Kamoun WS, et al. Endothelial focal adhesion kinase mediates cancer cell homing to discrete regions of the lungs via Eselectin upregulation[J]. Proc Natl Acad Sci U S A, 2011, 108(9): 3725-3730.
[22]Trovato R, Canè S, Petrova V, et al. The engagement between MDSCs and metastases: partners in crime[J]. Front Oncol, 2020, 10: 165.
[23]Sprouse ML, Welte T, Boral D, et al. PMNMDSCs enhance CTC metastatic properties through reciprocal interactions via ROS/Notch/Nodal signaling[J]. Int J Mol Sci, 2019, 20(8): 1916.
[24]Liu Q, Liao Q, Zhao Y. Myeloidderived suppressor cells (MDSC) facilitate distant metastasis of malignancies by shielding circulating tumor cells (CTC) from immune surveillance[J]. Med Hypotheses, 2016, 87: 34-39.
[25]Liu Y, Cao X. Characteristics and significance of the premetastatic niche[J]. Cancer Cell, 2016, 30(5): 668-681.
[26]Wang D, Sun H, Wei J, et al. CXCL1 is critical for premetastatic niche formation and metastasis in colorectal cancer[J]. Cancer Res, 2017, 77(13): 3655-3665.
[27]Zeng D, Wang M, Wu J, et al. Immunosuppressive microenvironment revealed by immune cell landscape in premetastatic liver of colorectal cancer[J]. Front Oncol, 2021, 11: 620688.
[28]Kitamura T, Fujishita T, Loetscher P, et al. Inactivation of chemokine (CC motif) receptor 1 (CCR1) suppresses colon cancer liver metastasis by blocking accumulation of immature myeloid cells in a mouse model[J]. Proc Natl Acad Sci U S A, 2010, 107(29): 13063-13068.
[29]Ren X, Xiao J, Zhang W, et al. Inhibition of CCL7 derived from MoMDSCs prevents metastatic progression from latency in colorectal cancer[J]. Cell Death Dis, 2021, 12(5): 484.
[30]Limagne E, Euvrard R, Thibaudin M, et al. Accumulation of MDSC and Th17 cells in patients with metastatic colorectal cancer predicts the efficacy of a FOLFOXBevacizumab drug treatment regimen[J]. Cancer Res, 2016, 76(18): 5241-5252.
[31]Yamagishi H, Kuroda H, Imai Y, et al. Molecular pathogenesis of sporadic colorectal cancers[J]. Chin J Cancer, 2016, 35: 4.
[32]Angelova M, Charoentong P, Hackl H, et al. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy[J]. Genome Biol, 2015, 16(1): 64.
[33]Lichtenstern CR, Ngu RK, Shalapour S, et al. Immunotherapy, inflammation and colorectal cancer[J]. Cells, 2020, 9(3): 618.
|